AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled ‘A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2)’. The study aims to evaluate the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension.
The intervention being tested is AZD3427, a drug administered via subcutaneous injection every two weeks over a 24-week period. The study involves three different dosage levels of AZD3427, alongside a placebo group.
This interventional study employs a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. The primary purpose is treatment-focused, aiming to assess the drug’s impact on the specified conditions.
The study began on April 24, 2023, with an expected primary completion date in 2025. The most recent update was submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
This study could significantly impact AstraZeneca’s market position, potentially boosting investor confidence if results are favorable. It also highlights AstraZeneca’s commitment to addressing complex cardiovascular conditions, setting a competitive edge in the pharmaceutical industry.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.